Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares OutstandingWages, Salaries and Other
Ratios

Corvus Pharmaceuticals (CRVS) Other Gross PP&E Adjustments (2016 - 2026)

Corvus Pharmaceuticals' Other Gross PP&E Adjustments history spans 12 years, with the latest figure at $1.9 million for Q1 2026.

  • Quarterly Other Gross PP&E Adjustments rose 60.4% to $1.9 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $1.9 million through Mar 2026, up 60.4% year-over-year, with the annual reading at $1.8 million for FY2025, 178.37% up from the prior year.
  • Other Gross PP&E Adjustments came in at $1.9 million for Q1 2026, up from $1.8 million in the prior quarter.
  • In the past five years, Other Gross PP&E Adjustments ranged from a high of $4.2 million in Q3 2024 to a low of -$2.8 million in Q4 2022.
  • The 5-year median for Other Gross PP&E Adjustments is $1.9 million (2026), against an average of $1.6 million.
  • The largest YoY upside for Other Gross PP&E Adjustments was 178.37% in 2025 against a maximum downside of 66.29% in 2025.
  • Corvus Pharmaceuticals' Other Gross PP&E Adjustments stood at -$2.8 million in 2022, then grew by 24.71% to -$2.1 million in 2023, then decreased by 9.48% to -$2.3 million in 2024, then soared by 178.37% to $1.8 million in 2025, then rose by 5.72% to $1.9 million in 2026.
  • Per Business Quant, the three most recent readings for CRVS's Other Gross PP&E Adjustments are $1.9 million (Q1 2026), $1.8 million (Q4 2025), and $1.7 million (Q3 2025).